Pembrolizumab for metastatic hepatocellular carcinoma following live donor liver transplantation: The silver bullet?

Hepatology. 2018 Mar;67(3):1166-1168. doi: 10.1002/hep.29575. Epub 2018 Jan 26.

Authors

Ashwin Rammohan¹, Mettu S Reddy¹, Mohammed Farouk¹, Joy Vargese¹, Mohamed Rela^{1

2}

Affiliations

¹ The Institute of Liver Disease & Transplantation, Global Hospitals & Health City, Chennai, India.
² Institute of Liver Studies, King's College Hospital, London, United Kingdom.

PMID: 29023959
DOI: 10.1002/hep.29575

No abstract available

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents, Immunological / therapeutic use*
Carcinoma, Hepatocellular / drug therapy*
Carcinoma, Hepatocellular / pathology
Humans
Liver / pathology
Liver / surgery
Liver Neoplasms / drug therapy*
Liver Neoplasms / pathology
Liver Transplantation / adverse effects
Living Donors
Male
Middle Aged
Tomography, X-Ray Computed

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
pembrolizumab